Auxly Cannabis Group (0UO5) AI Stock Analysis

0 Followers

Auxly Cannabis Group

(LSE:0UO5)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Above-market revenue and EBITDA growthStrong year-over-year revenue growth paired with faster adjusted EBITDA growth indicates improving operating leverage rather than growth purchased solely through higher spending. If sustained, this combination can strengthen earnings power, support reinvestment, and help Auxly outgrow the Canadian cannabis market.

Negative Factors

Recent margin compressionThe sharp reduction in gross margin shows that profitability remains exposed to cost or pricing pressure even after the turnaround. Sustained compression would reduce the cash available for capacity investment, weaken operating leverage, and make future earnings more sensitive to product mix and market pricing.

Auxly Cannabis Group Business Overview & Revenue Model

Company Description

Auxly Cannabis Group Inc. operates as a Canadian consumer packaged goods (CPG) firm focused on the cannabis market. Its primary activities include the development, manufacturing, and distribution of cannabis products, targeting both recreational and...

Auxly Cannabis Group Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|Next Earnings Date:Jun 01, 2020

Earnings Call SentimentPositive

The call was strongly positive, supported by quarterly records in revenue, adjusted EBITDA and cash flow, stable 56% gross margins, strong cash conversion, brand and product leadership, planned capacity expansion and a favorable Canadian market outlook. The main challenges were lower B2B volumes and prices, structural margin pressure in vapes, potential future distillate cost increases, evolving international regulations and incomplete national excise-stamp harmonization. Highlights significantly outweighed the lowlights.

Positive Updates

Record Q3 Financial Results

Q3 2026 delivered quarterly records in net revenue, adjusted EBITDA and cash flow from operations before working capital changes. Net revenue reached $49.5 million, up 24% year-over-year; adjusted EBITDA was $15.8 million, up 29% year-over-year, with a 32% EBITDA margin; and cash flow from operations before working capital changes reached $14.8 million, up 28% year-over-year.

Negative Updates

Lower B2B Sales Partially Offset Margin Gains

Higher cultivation yields, manufacturing improvements, efficiency gains and procurement initiatives were partially offset in the quarter by lower B2B sales volumes and prices, resulting in gross margin remaining at 56% on a net basis.

Company Guidance

Auxly expects to continue to grow net revenue above market rates through product innovation, continued investment in distribution and increased capacity at Auxly Leamington, with total capital expenditures of up to $30 million through the end of 2028 expected to increase production capacity by 30% from 2025 levels; it expects to commit between $10 million and $12 million of cash flow from operations to these projects in 2026, with a portion of the associated expenditures expected to occur in the first half of 2027. The company expects to maintain profitability and generate strong cash flow, target SG&A growth at the same rate as revenue growth, maintain its category gross margins within its margin envelope, and expects Q4 to be a strong quarter; it believes the Canadian market grows 5% a year between here and 2030, reaching a $6 billion or $7 billion market, and that it can grow faster than that 5% rate of market growth.

Auxly Cannabis Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0UO5 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:CRON	83Outperform	CAD 1.78B	21.01	5.35%	―	54.74%	60.60%
TSE:OGI	59Neutral	CAD 167.80M	1.83	21.99%	―	38.14%	2030.00%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:ACB	51Neutral	CAD 468.11M	-5.24	-15.33%	―	-22.16%	-30.78%
TSE:WEED	48Neutral	CAD 368.68M	-1.06	-39.36%	―	10.67%	74.14%

* Healthcare Sector Average

Performance Comparison

GB:0UO5 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:WEED	Canopy Growth	0.81	-0.66	-44.90%
TSE:OGI	Organigram Global Inc.	1.18	-0.94	-44.34%
TSE:ACB	Aurora Cannabis (US)	7.05	1.00	16.53%
TSE:CRON	Cronos Group (US)	4.82	1.42	41.76%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Auxly Cannabis Group AI Stock Analysis